Reviewer's report

Title: Severe Anterior Uveitis Complicating Zoledronic Acid Therapy in Breast Cancer

Version: 1 Date: 19 August 2005

Reviewer: James R Berenson

Reviewer's report:

General

--------------------------------------------------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

The authors should mention how to deal with the uveitis in terms of repeating the bisphosphonate treatment.

The only additional comment I would make is to reemphasize that the authors should mention how to deal with the uveitis in terms of repeating bisphosphonate treatment.

--------------------------------------------------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

Introduction: The most recently introduced bisphosphonate is not “alendronate bisodium” (which should read “disodium”) but zoledronic acid.

Discussion: The lack of reinstitution of zoledronic therapy because of the recurrence of the uveitis is not necessarily the correct treatment plan. In fact, patients have continued bisphosphonates who have developed uveitis without severe untoward effects. The authors should address this in the Discussion section.

--------------------------------------------------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)
What next?: Accept after minor essential revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

Within the past 5 years, I have received funding for both clinical and basic research, honoraria for speaking engagements and consulting fees from Novartis Pharmaceuticals, the manufacturer of Zometa.